Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000713769 | SCV000844399 | likely benign | not provided | 2017-12-22 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000713769 | SCV002944419 | likely benign | not provided | 2023-12-06 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004800556 | SCV005423200 | uncertain significance | not specified | 2024-10-16 | criteria provided, single submitter | clinical testing | Variant summary: TTBK2 c.2299G>A (p.Val767Met) results in a conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 4.8e-05 in 249544 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in TTBK2 causing Spinocerebellar Ataxia Type 11, allowing no conclusion about variant significance. To our knowledge, no occurrence of c.2299G>A in individuals affected with Spinocerebellar Ataxia Type 11 and no experimental evidence demonstrating its impact on protein function have been reported. ClinVar contains an entry for this variant (Variation ID: 586780). Based on the evidence outlined above, the variant was classified as uncertain significance. |